196 related articles for article (PubMed ID: 36451043)
21. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
23. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
25. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Malmgren J; Hurlbert M; Atwood M; Kaplan HG
Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
[TBL] [Abstract][Full Text] [Related]
26. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
27. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
28. The dynamics of HER2-low expression during breast cancer progression.
Anderson S; Bartow BB; Siegal GP; Huang X; Wei S
Breast Cancer Res Treat; 2023 Oct; 201(3):437-446. PubMed ID: 37433993
[TBL] [Abstract][Full Text] [Related]
29. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
30. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
[No Abstract] [Full Text] [Related]
31. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
Trillo P; Sandoval J; Trapani D; Nicolò E; Zagami P; Giugliano F; Tarantino P; Vivanet G; Ascione L; Friedlaender A; Esposito A; Criscitiello C; Curigliano G
Eur J Cancer; 2023 May; 185():119-130. PubMed ID: 36989828
[TBL] [Abstract][Full Text] [Related]
32. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
Kim JS; Kim K; Jung W; Shin KH; Im SA; Kim HJ; Kim YB; Chang JS; Kim JH; Choi DH; Park YH; Kim DY; Kim TH; Choi BO; Lee SW; Kim S; Kwon J; Kang KM; Chung WK; Kim KS; Yoon WS; Kim JH; Cha J; Oh YK; Kim IA
Breast Cancer Res Treat; 2021 Apr; 186(2):453-462. PubMed ID: 33392845
[TBL] [Abstract][Full Text] [Related]
33. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
34. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
[TBL] [Abstract][Full Text] [Related]
35. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
36. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
37. Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
Xu C; Wang Y; Hong Y; Yao R; Wu L; Shen X; Qu Y; Zhang Z; Zhu W; Yang Y; Chen W; Zhou Y; Liang Z
Breast Cancer Res Treat; 2023 Jun; 199(3):603-615. PubMed ID: 37084155
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Xie J; Zou Y; Gao T; Xie L; Tan D; Xie X
Cancer Control; 2022; 29():10732748221099230. PubMed ID: 35499382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
